Emergence of triplet therapy for metastatic castration-sensitive prostate cancer: An updated systematic review and network meta-analysis

Sathianathen, Niranjan; Pan, Henry Y.C.; Lawrentschuk, Nathan; Azad, Arun; Bolton, Damien; Murphy, Declan

doi:10.1016/j.urolonc.2022.10.016

Cited by 14 publications

(6 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…More than 60% of all postoperative complications were not reported, and the accuracy of reported complications was only 33.3%. According to the literature, under-reporting of postoperative complications is a well-documented problem in surgery [22][23][24][25][26]. Several studies have shown that the true incidence of postoperative complications is often higher compared to the numbers reported in medical records and published studies [27,28].…”

Section: Discussionmentioning

confidence: 99%

Incidence of postoperative complications is underestimated if outcome data are recorded by interns and first year residents in a low volume hospital setting

Raguz,

Meissner,

Ahlen

et al. 2023

Preprint

View full text Add to dashboard Cite

Quality of outcome measurement in a district hospital is poor if done by unexperienced residents and significantly underestimates the true complication rate. Outcome measurement must be done or supervised by experienced surgeons to ensure correct and reliable outcome data. The aim of this study is to evaluate the accuracy of outcome reporting after elective visceral surgery in a low volume district hospital. Outcome measurement as well as transparent reporting of surgical complications becomes more and more important. In the future, financial and personal resources may be distributed due to reported quality and thus, it is in the main interest of healthcare providers that outcome data are accurately collected. Between 10/ 2020 and 09/ 2021 postoperative complications during the hospitalisation were recorded using the Clavien - Dindo classification (CDC) and comprehensive complication index (CCIâ) by residents of a surgical department in a district hospital. After one year of prospective data collection, data were retrospectively analyzed and re-evaluated for accuracy by senior consultant surgeons. In 575 patients undergoing elective general or visceral surgery interns and residents reported an overall rate of patients with complications of 7.3% (n=42) during the hospitalization phase, whereas a rate of 18.3% (n=105) was revealed after retrospective analysis by senior consultant surgeons. Thus, residents failed to report postoperative complications in 60% of cases (63/105). In the 42 cases, in which complications were initially reported, the grading of complications was correct only in 33.3% of cases (n=14). Complication grades that were most missed were CDC grade I and II.

show abstract

Section: Discussionmentioning

confidence: 99%

Incidence of postoperative complications is underestimated if outcome data are recorded by interns and first year residents in a low volume hospital setting

Raguz,

Meissner,

Ahlen

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Однако при интерпретации этих данных важно отметить, что некоторые пациенты с мГЧРПЖ в этом исследовании также получали локальную лучевую терапию, что, безусловно, оказало влияние на продолжительность ОВ и безрецидивной выживаемости, но не имело отражения в интерпретации полученных результатов. В то же время существуют четкие объективные данные, демонстрирующие, что тройная комбинированная терапия, включающая АДТ + абиратерон + доцетаксел, превосходит двойную комбинированную терапию с лучшими показателями ОВ (АДТ + абиратерон) при мГЧРПЖ с большим объемом метастатического поражения (ОР для ОВ 0,52 против 0,61) [19][20][21][22][23].…”

Section: объем метастатического пораженияunclassified

Effectiveness and safety of darolutamide as a component of combination therapy in patients with prostate cancer

Alekseev,

Perepukhov,

Nyushko

2024

Onkourologiâ

View full text Add to dashboard Cite

Prostate cancer is an extremely important problem in current urologic oncology. For a long time, the golden standard of treatment of common forms of prostate cancer at the stage of distant metastases was androgen deprivation therapy directed at suppression of native testosterone level. Combination treatment using long-term androgen deprivation therapy and new generation antiandrogens is currently a scientifically substantiated conceptually new standard of therapy which has replaced treatment paradigm using androgen deprivation therapy as a monotherapy in patients with metastatic hormone-sensitive prostate cancer. The article presents the results of large trials performed in patients with metastatic hormone-sensitive prostate cancer and characterizes the role of one of the most effective and safe drugs, darolutamide, used to treat patients of this subgroup.

show abstract

“…Sin embargo, estos metaanálisis han mostrado resultados heterogéneos en cuanto al beneficio de añadir docetaxel al tratamiento (52)(53)(54)(55). La evidencia apoya el uso de la triple terapia en pacientes con mCPSC con alta carga tumoral, con la adición de inhibidores de la vía del receptor de andrógenos (ARPI) al doblete de tratamiento con ADT y docetaxel (56-57); sin embargo, surge la controversia sobre la magnitud del beneficio mediante la adición de docetaxel al doblete de tratamiento con ADT y ARPI (58-60); y hasta la fecha, los datos disponibles no resuelven esta pregunta.…”

Section: Taxanos En Cáncer De Próstata Hormono-naïveunclassified

Chemotherapy in hormono-naïve prostate cancer

Marmolejo,

Morales-Barrera,

González

et al. 2024

Rev Cancer

View full text Add to dashboard Cite

Conflicto de intereses: los autores declaran no tener conflicto de interés. RESUMENEl paradigma de tratamiento del cáncer de próstata metastásico ha evolucionado rápidamente en los últimos años. El pilar del tratamiento en la enfermedad metastásica continúa siendo la terapia de deprivación de andrógenos, pero la intensificación del tratamiento con la adición de quimioterapia y de los nuevos inhibidores de la vía del receptor de andrógenos (dobletes y tripletes) han proporcionado mejoras significativas en la supervivencia en el escenario hormono-sensible, retrasando la progresión a la resistencia a la castración y mejorando la calidad de vida de los pacientes. Sin embargo, surgen controversias sobre el beneficio de la 1 terapia de intensificación y la selección óptima del tratamiento según el escenario clínico de cada paciente.

show abstract

Emergence of triplet therapy for metastatic castration-sensitive prostate cancer: An updated systematic review and network meta-analysis

Cited by 14 publications

References 48 publications

Incidence of postoperative complications is underestimated if outcome data are recorded by interns and first year residents in a low volume hospital setting

Incidence of postoperative complications is underestimated if outcome data are recorded by interns and first year residents in a low volume hospital setting

Effectiveness and safety of darolutamide as a component of combination therapy in patients with prostate cancer

Chemotherapy in hormono-naïve prostate cancer

Contact Info

Product

Resources

About